Cardiomyocyte resistance to doxorubicin mediated by A3 adenosine receptor

Journal of Molecular and Cellular Cardiology

Volumn 34, Issue 5, 2002, Pages 493-507

  Shneyvays, Vladimir ^a   Mamedova, Liaman K ^a   Korkus, Avishag ^a   Shainberg, Asher ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Actin; Adenosine receptors; Apoptosis; Cardioprotection; Desmin; Doxorubicin; Lysosomes; Necrosis

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; 2 CHLORO N 6 (3 IODOBENZYL)ADENOSINE 5' N METHYLURONAMIDE; ADENOSINE A3 RECEPTOR; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR STIMULATING AGENT; ADENOSINE TRIPHOSPHATE; ANTHRACYCLINE; DESMIN; DIAZOXIDE; DOXORUBICIN; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM ION; UNCLASSIFIED DRUG;

ACIDIFICATION; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL MEMBRANE POTENTIAL; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG RESISTANCE; HEART MUSCLE CELL; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; LYSOSOME; MITOCHONDRIAL MEMBRANE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION;

EID: 0036586723     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.2002.1532     Document Type: Article

References (46)

1. 3 adenosine receptor protects against doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 2001; 33: 1249-1261.
2. MURPHY GP, LAWRENCE WJ, LENHARD REE. American Society Textbook of Oncology, 2nd Edition. Atlanta, GA: American Cancer Society, 1995.
3. ETTINGHAUSEN SE, BONOW RO, PALMERI ST, SEIPP CA, STEINBERG SM, WHITE DE, ROSENBERG SA. Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. Arch Surg 1986; 121: 1445-1451.
4. SKLADANOWSKI A, KONOPA J. Relevance of interstrand DNA crosslinking induced by anthracyclines for their biological activity. Biochem Pharmacol 1994; 47: 2279-2287.
5. SERRANO J, PALMEIRA CM, KUEHL DW, WALLACE KB. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta 1999; 1411: 201-205.
6. DELPY E, HATEM SN, ANDRIEU N, DE VAUMAS C, HENAFF M, RUCKER-MARTIN C, JAFFREZOU JP, LAURENT G, LEVADE T, MERCHADER JJ. Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc Res 1999; 43: 398-407.
7. KUMAR D, KIRSHENBAUM L, LI T, DANELISEN I, SINGAL P. Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Ann N Y Acad Sci 1999; 874: 156-168.
8. ADDERLEY SR, FITZGERALD DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 1999; 274: 5038-5046.
9. KANG YJ, ZHOU ZX, WANG GW, BURIDI A, KLEIN JB. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem 2000; 275: 13690-13698.
10. AROLA OJ, SARASTE A, PULKKI K, KALLAJOKI M, PARVINEN M, VOIPIO-PULKKI LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000; 60: 1789-1792.
11. NEGORO S, OH H, TONE E, KUNISADA K, FUJIO Y, WALSH K, KISHIMOTO T, YAMAUCHI-TAKIHARA K. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 2001; 103: 555-561.
12. HERMAN EH, ZHANG J, HASINOFF BB, CLARK JR JR. FERRANS VJ. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J Mol Cell Cardiol 1997; 29: 2415-2430.
13. ZHANG J, CLARK JR JR, HERMAN EH, FERRANS VJ. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J Mol Cell Cardiol 1996; 28: 1931-1943.
14. SHINEYVAYS V, SAFRAN N, HALILI-RUTMAN I, SHAINBERG A. Insights into adenosine A1 and A3 receptors function: cardiotoxicity and cardioprotection. Drug Dev Res 2000; 50: 324-337.
15. KUNISADA K, NEGORO S, TONE E, FUNAMOTO M, OSUGI T, YAMADA S, OKABE M, KISHIMOTO T, YAMAUCHI-TAKIHARA K. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA 2000; 97: 315-319.
16. 3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2 H3 mast cells from apoptosis. Mol Pharmacol 2001; 59: 76-82.
17. 3 adenosine receptor activation and its suppression by isoproterenol. Exp Cell Res 2000; 257: 111-126.
18. SHNEYVAYS V, NAWRATH H, JACOBSON KA, SHAINBERG A. Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist. Exp Cell Res 1998; 243: 383-397.
19. PARSONS M, YOUNG L, LEE JE, JACOBSON KA, LIANG BT. Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D. FASEB J 2000; 14: 1423-1431.
20. FREDHOLM BB, ARSLAN G, HALLDNER L, KULL B, SCHULTE G, WASSERMAN W. Structure and function of adenosine receptors and their genes. Naunyn-Schmiedeberg's Arch Pharmacol 2000; 362: 364-374.
21. DE BEER EL, BOTTONE AE, VOEST EE. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. Eur J Pharmacol 2001; 415: 1-11.
22. TEWEY KM, ROWE TC, YANG L, HALLIGAN BD, LIU LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-468.
23. KELLOGG GE, SCARSDALE JN, FORNARI FA JR. Identification and hydropathic characterization of structural features affecting sequence specificity for doxorubicin intercalation into DNA double-stranded polynucleotides. Nucleic Acids Res 1998; 26: 4721-4732.
24. BOBRYSHEV YV, BABAEV VR, LORD RS, WATANABE T. Cell death in atheromatous plaque of the carotid artery occurs through necrosis rather than apoptosis. In Vivo 1997; 11: 441-452.
25. WYLLIE AH, KERR JF, CURRIE AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68: 251-306.
26. TAKEMURA G, OHNO M, FUJIWARA H. Ischemic heart disease and apoptosis. Rinsho Byori 1997; 45: 606-613.
27. OHNO M, TAKEMURA G, OHNO A, MISAO J, HAYAKAWA Y, MINATOGUCHI S, FUJIWARA T, FUJIWARA H. "Apoptotic" myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis by immunogold electron microscopy combined with in situ nick end-labeling. Circulation 1998; 98: 1422-1430.
28. KANOH M, TAKEMURA G, MISAO J, HAYAKAWA Y, AOYAMA T, NISHIGAKI K, NODA T, FUJIWARA T, FUKUDA K, MINATOGUCHI S, FUJIWARA H. Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. Circulation 1999; 99: 2757-2764.
29. BURGOYNE LA. The mechanisms of pyknosis: hypercondensation and death. Exp Cell Res 1999; 248: 214-222.
30. AUNER HW, TINCHON C, LINKESCH W, HALWACHS-BAUMANN G, SILL H. Correspondence re: O. J. Arola et al., acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2001; 61: 2335-2336.
31. SCHAPER J, HEIN S, KOSTIN S. Structural alterations in the failing human heart. Meeting of the Israel Heart Society (Abstracts). Caesarea. Israel, April-May 2001.
32. MINOTTI G, LICATA S, SAPONIERO A, MENNA P, CALAFIORE AM, DI GIAMMARCO G, LIBERI G, ANIMATI F, CIPOLLONE A, MANZINI S, MAGGI CA. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite. Chem Res Toxicol 2000; 13: 1336-1341.
33. IDE T, TSUTSUI H, HAYASHIDANI S, KANG D, SUEMATSU N, NAKAMURA K, UTSUMI H, HAMASAKI N, TAKESHITA A. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001; 88: 529-535.
34. MUBAGWA K, FLAMENG W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 2001; 52: 25-39.
35. ATP channel is associated with increased mitochondrial oxygen consumption. Acad Emerg Med 2001; 8: 549.
36. WANG E, LEE MD, DUNN KW. Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells. J Cell Physiol 2000; 184: 263-274.
37. SINGAL PK, MACLEOD B, DEALLY CM. Adriamycin-induced leakage of lysosomal enzymes in vitro. Mol Cell Biochem 1988; 81: 89-94.
38. BHALLA KS, WILCZYNSKI SW, ABUSHAMAA AM, PETROS WP, MCDONALD CS, LOFTIS JS, CHAO NJ, VREDENBURGH JJ, FOLZ RJ. Pulmonary toxicity of induction chemotherapy prior to standard- or high-dose chemotherapy with autologous hematopoietic support. Am J Respir Crit Care Med 2000; 161: 17-25.
39. AMBLER GR, JOHNSTON BM, MAXWELL L, GAVIN JB, GLUCKMAN PD. Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor I. Cardiovasc Res 1993; 27: 1368-1373.
40. 3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J Mol Cell Cardiol 2001; 33: 825-830.
41. HEIN S, KOSTIN S, HELING A, MAENO Y, SCHAPER J. The role of the cytoskeleton in heart failure. Cardiovasc Res 2000; 45: 273-278.
42. LI Z, MERICSKAY M, AGBULUT O. BUTLER-BROWNE G, CARLSON L, THORNELL LE, BABINET C, PAULIN D. Desmin is essential for the tensile strength and integrity of myofibrils but not for myogenic commitment, differentiation, and fusion of skeletal muscle. J Cell Biol 1997; 139: 129-144.
43. KAY L, LI Z, MERICSKAY M, OLIVARES J, TRANQUI L, FONTAINE E, TIIVEL T, SIKK P, KAAMBRE T, SAMUEL JL, RAPPAPORT L, USSON Y, LEVERVE X, PAULIN D, SAKS VA. Study of regulation of mitochondrial respiration in vivo. An analysis of influence of ADP diffusion and possible role of cytoskeleton. Biochim Biophys Acta 1997; 1322: 41-59.
44. 3 adenosine receptor stimulation modulates sarcoplasmic reticulum Ca(2 +) release in rat heart. Cardiovasc Res 2001; 50: 56-64.
45. MAGGIWAR SB, DHANRAJ DN, SOMANI SM, RAMKUMAR V. Adenosine acts as an endogenous activator of the cellular antioxidant defense system. Biochem Biophys Res Commun 1994; 201: 508-515.
46. RAMKUMAR V, NIE Z, RYBAK LP, MAGGIEWAR SB. Adenosine, antioxidant enzymes and cytoprotection. Trends Pharmacol Sci 1995; 16: 283-285.